Infectious Disease

Marilyn Bulloch, PharmD, discusses the persistent burden of hepatitis B, evolving adult vaccination recommendations, and how pharmacists can improve vaccine uptake through accessible, stigma-free patient counseling.

New findings reveal that mouse liver cells can form the viral template behind chronic HBV infection.

Ivermectin, vitamin D, and zinc are being recommended on social media as treatment for hantavirus—despite a lack of evidence.

A new study describes the high symptom burden carried by pediatric long COVID patients and highlights integrative medicine's role in their care.

The World Health Organization confirmed the outbreak is the Andes strain, the only known human transmissible hantavirus.

FDA leaders reportedly delay vaccine safety findings on COVID-19 and shingles shots, raising transparency concerns and new challenges for pharmacists.

A hantavirus outbreak aboard a cruise ship is raising urgent concerns about the dangers of this rare but deadly rodent-borne virus.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

A large multicohort analysis highlights obesity as a modifiable risk factor for severe infectious outcomes, reinforcing the pharmacist’s role in prevention, vaccination, and chronic disease management.

The approval of doravirine and islatravir marks a new 2-drug, once-daily oral option for HIV-1 management, with implications for treatment simplification, adherence, and pharmacist-led antiretroviral care.

High pneumococcal community-acquired pneumonia burden in older adults highlights the critical role of pharmacists in driving 21-valent vaccine uptake and patient-centered prevention strategies.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Experts describe how infectious disease pharmacists drive antimicrobial stewardship, tackle resistance, and shape global training as SIDP marks 35 years.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

Using PEPFAR-backed HIV treatment in Zambia as minerals leverage will risk resistance, deaths, and US global health leadership.

The CDC testing pause disrupts diagnostic testing for infectious diseases like rabies and mpox, leaving pharmacists and states scrambling for answers.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

At APhA 2026, Damika Walker, PharmD, RPh, argued that closing stubbornly low adult vaccination rates requires a shift in how pharmacists approach every patient encounter.

With updated recommendations for adults aged 50 and older, pharmacy teams are uniquely positioned to bridge gaps in care through community engagement and proactive clinical assessments.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Jacinda “JAM" Abdul-Mutakabbir, PharmD, MPH, discusses the adult burden of respiratory syncytial virus (RSV) and the critical role of pharmacists in vaccine access and education—especially for marginalized populations.